Log in

Relevant bibliographies by topics / Tyrosine Kinase Inhibitors (TKIs) / Books

To see the other types of publications on this topic, follow the link: Tyrosine Kinase Inhibitors (TKIs).

Books on the topic 'Tyrosine Kinase Inhibitors (TKIs)'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 18 books for your research on the topic 'Tyrosine Kinase Inhibitors (TKIs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Focosi, Daniele, ed. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46091-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

D, Fabbro, and McCormick Frank 1950-, eds. Protein tyrosine kinases: From inhibitors to useful drugs. Humana Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rommel, Christian. Phosphoinositide 3-kinase in Health and Disease: Volume 2. Springer-Verlag Berlin Heidelberg, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Matthews, David J. Targeting protein kinases for cancer therapy. John Wiley & Sons, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing AG, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

McCormick, Frank. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

McCormick, Frank, and Doriano Fabbro. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

(Editor), Doriano Fabbro, and Frank McCormick (Editor), eds. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Full text

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling

APA, Harvard, Vancouver, ISO, and other styles

12

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 1. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-Kinase in Health and Disease: Volume 2. Springer Berlin / Heidelberg, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 2. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rommel, Christian, Peter K. Vogt, and Bart Vanhaesebroeck. Phosphoinositide 3-kinase in Health and Disease: Volume 1. Springer, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text

Abstract:

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor

APA, Harvard, Vancouver, ISO, and other styles

17

Kuwabara, Satoshi. Neuromuscular junction disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199658602.003.0014.

Full text

Abstract:

Ten seminal papers on disorders of the neuromuscular junction are described, covering historical aspects, recent advances in immunological, biological, and genetic researches, and future perspectives. Early descriptions of myasthenia gravis (MG) date back to the seventeenth century, and MG acquired its name in the nineteenth century. The first symptomatic treatment with cholinesterase inhibitors was reported in 1934, leading to the development of modern immunological therapies. Following the discovery of anti-MuSK (muscle-specific tyrosine kinase) antibody in 2001, MG is currently classified i

APA, Harvard, Vancouver, ISO, and other styles

18

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!